The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1643
ISSUE 1643
February 7, 2022
Issue 1643
- Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
- Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus
- Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
- Drugs for Acute Otitis Media in Children
- Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
- Treatment of COVID-19 in High-Risk Outpatients (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
February 7, 2022 (Issue: 1643)
The FDA has approved Vuity (Abbvie), a 1.25%
ophthalmic solution of the muscarinic receptor
agonist pilocarpine hydrochloride, for treatment of
presbyopia in adults. Pilocarpine 1%, 2%, and 4%
ophthalmic solutions (Isopto Carpine, and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.